Global Septic Arthritis Market Size, Share, Forecast Report, 2020-2027

Septic arthritis is a disease caused by a bacterial infection or invasion in the joints leading to inflammation. Symptoms of septic arthritis include redness, heat, and pain in the joints reducing their movement. It is caused by bacteria, viruses, fungi, and parasites. Diabetes, osteoarthritis, gout, rheumatoid arthritis, joint trauma and poor immune function are major risk factors for septic arthritis.

The market for septic arthritis is driven by an increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, availability of cost effective treatment and extensive research and development activities in internal medicine. There is an increasing demand for the new drugs for the treatment of septic arthritis which further fuels the growth of the market.

Bacterial resistance to commonly used antibiotics such as vancomycin may restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrants in the market.

The global septic arthritis market is expected to grow at a CAGR of 7.5% during the forecast period.

Segments

The global septic arthritis market is segmented on the basis of diagnosis, treatment, indication, and end user.

On the basis of diagnosis, market is segmented into joint fluid analysis, blood tests, imaging and others. Imaging is further segmented into X-ray, ultrasonography, MRI, and CT scan.

On the basis of treatment, the market is segmented into antibiotics, aspiration of the joint, surgery, and others. Surgery is further segmented into arthrotomy and arthroscopy.

On the basis of indication, the market is segmented into arthritis, hip or knee prosthesis, poor immune function, joint surgery, and others.

On the basis of end user, the market is segmented into orthopedic hospitals, clinics, pharmaceutical companies, and others.
Key Players in the Global Septic Arthritis Market

Some of the key players in this market are Lupin Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Swtizerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Inc. (U.S.), and Pfizer (U.S.).